Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM01 (tidapaxicept) plus tislelizumab vs investigator's choice chemotherapy in PD-(L)1–refractory classical Hodgkin lymphoma
CTR20241938Phase 3Active
- Sponsor
- ImmuneOnco
- Start
- Jul 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tidapaxicept in classical Hodgkin lymphoma (cHL), sponsored by ImmuneOnco. Started Jul 2024; status: active.
02
Drugs
tidapaxicept
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20241938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241938.